Medicus Pharma Ltd.: announces 50-to-1 share consolidation

What happened Medicus Pharma Ltd announced that it will effect a 50-to-1 consolidation (the "Share Consolidation") of the company's common shares, no par value, to be effective Oct 12, 2026. The filing states the Share Consolidation is intended to increase the bid price of the common shares and to enable the company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The common shares are expected to begin trading on a consolidated basis at the commencement of trading on Oct 12, 2026, with a new CUSIP of 58471K301 and a new ISIN of CA58471K3010; the company's name and ticker "MDCX" will remain unchanged. The filing notes that at the company's 2026 annual general and special meeting held on Jun 3, 2026, shareholders authorized the board to effect a consolidation at a ratio of up to 50-to-1, and the board has approved the Share Consolidation pursuant to that authorization.

Key details

• Every 50 pre-consolidation common shares will be automatically exchanged for 1 post-consolidation common share.
• No fractional shares will be issued; holders otherwise entitled to fractional shares will be rounded down and paid cash in lieu for such fractional amounts.
• Positions held through brokers or nominees will be adjusted automatically subject to brokers' processes; registered book-entry holders need take no further action.
• Proportionate adjustments will be made to per share exercise prices and numbers of shares issuable under outstanding equity awards, convertible securities, warrants, and the company's equity incentive plans.

Why it may matter This item was reported under Item 8.01 (Other events) and covers the company's announcement of the Share Consolidation, its timing, new CUSIP and ISIN, and adjustments to outstanding equity instruments. The filing does not explain why the company acted.